NexGel Exclusive License Agreement With Celularity

NexGel, Inc. entered into an Asset Purchase and Exclusive License Agreement effective March 6, 2026 with Celularity Inc. Celularity is the licensor and NexGel is the licensee.

The agreement covers Celularity’s proprietary Licensed Patent Rights, Licensed Marks, and Licensed Know-How tied to its Degenerative Disease business segment products, including Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl, Centaflex, Project Spark, Project Fuse, and Project Orchid. The license is exclusive for NexGel to develop and commercialize Licensed Products, and it excludes rights related to Celularity’s Cell Therapy and BioBanking business segment products.

The exhibit notes that certain information was omitted because it was not material and would be competitively harmful if publicly disclosed.